To provide further conclusive evidence in vivo experiments, we will further demonstrate the therapeutic effect of the PI3K/AKT/mTOR signaling pathway inhibitors on CCA with high DCLK1 expression by constructing animal models. Here, AKT1 is linked to cholangiocarcinoma.